contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-agreement-mr-prof-dr-karl-diehl-starts-up-with-corethermr-treatments-in-austria

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ProstaLund operates in medical technology. Today, specialisation is mainly in the area of treatment of benign prostate enlargement (BPH). Through the company CoreTherm, heat treatment of benign prostate enlargement is offered, without the need for surgical operation. The vision is to offer both faster and more efficient solutions against traditional forms of infestation. The company was founded in 1991 and is operating globally, based in Lund.

ProstaLund

ProstaLund has signed an agreement on CoreTherm® with MR Prof. Dr Karl Diehl. The agreement means that MR Prof. Dr Karl Diehl has purchased a CoreTherm® machine and that ProstaLund will educate...

<div class="mfn-body"><p>ProstaLund has signed an agreement on CoreTherm® with MR Prof. Dr Karl Diehl. The agreement means that MR Prof. Dr Karl Diehl has purchased a CoreTherm® machine and that ProstaLund will educate, sell instruments for CoreTherm® treatments and service the machine. The first CoreTherm® treatments are planned to be performed during the third quarter.</p><p>‘It is great news that we are now taking the step into Europe in line with the company's presented strategy, and that we get the opportunity to show and train future new customers in a central location in Europe’ says Anders Kristensson, CEO ProstaLund AB.</p></div><div class="mfn-footer mfn-43458186cf95"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Anders Kristensson,&nbsp;CEO<br>Tel. +46 (0) 769 42 12 16<br>Email: anders.kristensson@prostalund.com</p></div><div class="mfn-footer mfn-about mfn-6fe429febaf6"><p><strong class="mfn-heading-1">About ProstaLund</strong></p><hr><p>ProstaLund AB (publ) is a Swedish medtech company with a headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement. The company has patented the CoreTherm® Concept treatment method, a customised thermal treatment for BPE (Benign Prostatic Enlargement). ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. See also - www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden</p><p><strong>Certified Adviser</strong>:<br>Västra Hamnen Corporate Finance AB<br>Phone: +46 40 200 250<br>E-mail: <a rel="noopener" href="mailto:ca@vhcorp.se">ca@vhcorp.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/83392197-9fe9-4799-b249-a2e07768bea8/new-agreement-mr-prof-dr-karl-diehl-starts-up-with-coretherm-r-treatments-in-austria.pdf" class="mfn-generated mfn-primary">New agreement - MR Prof. Dr Karl Diehl starts up with CoreTherm® treatments in Austria</a></p></div>

New agreement - MR Prof. Dr Karl Diehl starts up with CoreTherm® treatments in Austria